Engineered imine reductases and methods for the reductive amination of ketone and amine compounds

Patent metadata

Field	Value
Publication number	US-11352609-B2
Application number	US-202017010709-A
Country	US
Kind code	B2
Filing date	Sep 2, 2020
Priority date	Nov 25, 2014
Publication date	Jun 7, 2022
Grant date	Jun 7, 2022

Abstract

The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

First claim

What is claimed is:

1. An engineered polypeptide comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO:8, wherein the amino acid sequence of the engineered polypeptide has aspartate at the position corresponding to amino acid 198 of SEQ ID NO: 8, wherein the valine corresponding to amino acid 283 of SEQ ID NO: 8 is substituted with a different amino acid in the amino acid sequence of the engineered polypeptide, and wherein the engineered polypeptide has imine reductase activity.

2. The engineered polypeptide of claim 1 , wherein the amino acid sequence of the engineered polypeptide further comprises at least one additional substitution as compared to the amino acid sequence of SEQ ID NO:4, at a position selected from the group consisting of: X153, X167, X265, X262, X108, X234, X284, X282, X220, X272, X256, X267, X242, X281, X197, X277, X224, and X143.

3. The engineered polypeptide of claim 1 , wherein the amino acid sequence of the engineered polypeptide further comprises at least one additional substitution as compared to the amino acid sequence of SEQ ID NO:6, at a position selected from the group consisting of: X262, X9, X259, X220, X267, X153, X279, X200, X224, X256, X137, X143, X260, X261, X154, X276, and X185.

4. The engineered polypeptide of claim 1 , wherein the amino acid sequence of the engineered polypeptide further comprises at least one additional substitution as compared to the amino acid sequence of SEQ ID NO: 8, at a position selected from the group consisting of: X12, X31, X37, X44, X46, X48, X55, X56, X65, X82, X93, X98, X108, X137, X138, X141, X142, X143, X153, X154, X155, X156, X159, X166, X168, X173, X177, X178, X184, X185, X195, X197, X199, X200, X201, X203, X205, X206, X210, X213, X215, X216, X218, X220, X221, X223, X226, X234, X239, X242, X245, X251, X253, X256, X257, X259, X260, X261, X262, X263, X265, X266, X267, X268, X269, X273, X274, X277, X278, X279, X280, X281, X282, X284, X285, X289, X290, X291, X292, X293, X294, X330, and X349.

5. The engineered polypeptide of claim 1 , wherein the imine reductase activity comprises converting the ketone substrate

and the amine substrate

to produce the amine product compound

under suitable reaction conditions.

6. The engineered polypeptide of claim 5 , wherein the imine reductase activity in converting the ketone and amine substrate compound pair to the amine product compound under suitable reaction conditions is increased at least 2-fold as compared to the corresponding activity of an imine reductase polypeptide comprising the amino acid sequence of SEQ ID NO: 4.

Assignees

• Codexis Inc

Inventors

• Alvizo Oscar
• Mayo Melissa Ann
• Moore Jeffrey C

Classifications

• C12P13/001

  Amines; Imines · CPC title

• C07K14/195

  from bacteria · CPC title

• C12N9/0028 Primary

  with NAD or NADP as acceptor (1.5.1) · CPC title